Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

High-dose vegf antagonist regimens: BayerRecent Research Landscape

Frequent intravitreal injections increase patient non-compliance and clinical overhead risks. Engineering high-dose molar concentrations extends therapeutic durability to reduce injection frequency.

What technical problems is Bayer addressing in High-dose vegf antagonist regimens?

Uncontrolled pathological blood coagulation

(8)evidences

Endogenous natriuretic peptides suffer from rapid proteolytic degradation and renal clearance. Extending their functional presence in systemic circulation enables sustained therapeutic signaling for cardiovascular conditions.

Insufficient therapeutic duration

(8)evidences

Standard dosing intervals create significant patient burden and clinical non-compliance. Reducing treatment frequency prevents vision loss associated with undertreatment.